News from imprimis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 13, 2014, 16:30 ET

Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable...

Jul 24, 2014, 08:00 ET

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and...

Jun 24, 2014, 08:00 ET

Imprimis Pharmaceuticals Go Dropless™ Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy

 Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality,...

May 28, 2014, 08:00 ET

Imprimis Pharmaceuticals to Exhibit Go Dropless™ Cataract Surgery Formulations at 2014 Kiawah Eye Meeting

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality,...

Apr 22, 2014, 08:00 ET

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and...

Mar 25, 2014, 06:00 ET

Imprimis Pharmaceuticals Scheduled to Present at 13th Annual Needham Healthcare Conference

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Mar 04, 2014, 06:00 ET

Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Feb 25, 2014, 06:00 ET

Imprimis Pharmaceuticals' Pre-Commercial Ophthalmic Formulations to be Presented at 2014 American-European Congress of Ophthalmic Surgery (ACOS™)/Dulaney Winter Meeting

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Feb 19, 2014, 06:00 ET

Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Feb 11, 2014, 06:00 ET

Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulations

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Jan 28, 2014, 06:00 ET

Imprimis Pharmaceuticals to Exhibit Pre-Commercial Ophthalmic Formulations At 2014 ACES/SEE Caribbean Eye Meeting

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Dec 09, 2013, 08:00 ET

Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a pharmaceutical company focused on commercial development of novel drug formulations and drug...

Nov 19, 2013, 08:00 ET

Imprimis Optimistic After Congressional Passage of the Drug Quality and Security Act

 Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and...

Nov 12, 2013, 08:00 ET

Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek as Vice-President of Commercialization for its Ophthalmology Division

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians...

Nov 08, 2013, 13:36 ET

Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by...

Nov 06, 2013, 08:00 ET

Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians...

Aug 28, 2013, 08:00 ET

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of drug formulations through a growing proprietary network...

Aug 12, 2013, 08:00 ET

Imprimis Pharmaceuticals, Inc. Comments on Delay in Phase III Impracor™ Program

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug...

Aug 05, 2013, 08:30 ET

Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2)...

Jul 23, 2013, 08:30 ET

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Bleeding and Clotting Disorder Functional Antibiotic Drug Candidate

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug...